论文标题
深度学习的目标和可重现的骨肉瘤化疗反应评估和结果预测
Deep Learning-Based Objective and Reproducible Osteosarcoma Chemotherapy Response Assessment and Outcome Prediction
论文作者
论文摘要
骨肉瘤是最常见的原发性骨癌,其标准治疗包括术前化疗,然后切除。化学疗法反应用于预测患者的预后和进一步治疗。坏死在切除标本上的组织学幻灯片通常评估了坏死比定义为坏死肿瘤与总体肿瘤的比率。已知坏死比> = 90%的患者的预后更好。多个载玻片对坏死比的手动微观综述是半定量性的,并且可能具有观察者间和观察者间的变异性。我们提出了一种基于根基学习的客观和可重复的深度学习方法,以估算坏死比,并从扫描的苏木精和曙红全幻灯片图像预测结果。我们以3134 WSI的成绩收集了103例骨肉瘤病例,以训练我们的深度学习模型,验证坏死比评估并评估结果预测。我们训练了深层多磁化网络,以分割多个组织亚型,包括生存的肿瘤和像素级中的坏死肿瘤,并计算来自多个WSI的病例级坏死比。我们显示了通过我们的分割模型估算的坏死比,与由专家手动评估的病理报告高度相关,其中IV级的绝对差异(100%),III(> = 90%)和II(> = 50%和<90%和<90%)的绝对差异为4.4%,4.4%,4.4%,4.4%,和17.8%,均为4.4%,和17.8%。我们成功地分层了患者,以预测p = 10^-6的总体存活,而无进展的生存率为p = 0.012。我们可再现的方法没有可变性,使我们能够调整截止阈值,特别是针对我们的模型和数据集的截止阈值,为80%的OS和60%的PFS。我们的研究表明,深度学习可以支持病理学家作为一种客观的工具,可以分析组织学中骨肉瘤,以评估治疗反应并预测患者的结果。
Osteosarcoma is the most common primary bone cancer whose standard treatment includes pre-operative chemotherapy followed by resection. Chemotherapy response is used for predicting prognosis and further management of patients. Necrosis is routinely assessed post-chemotherapy from histology slides on resection specimens where necrosis ratio is defined as the ratio of necrotic tumor to overall tumor. Patients with necrosis ratio >=90% are known to have better outcome. Manual microscopic review of necrosis ratio from multiple glass slides is semi-quantitative and can have intra- and inter-observer variability. We propose an objective and reproducible deep learning-based approach to estimate necrosis ratio with outcome prediction from scanned hematoxylin and eosin whole slide images. We collected 103 osteosarcoma cases with 3134 WSIs to train our deep learning model, to validate necrosis ratio assessment, and to evaluate outcome prediction. We trained Deep Multi-Magnification Network to segment multiple tissue subtypes including viable tumor and necrotic tumor in pixel-level and to calculate case-level necrosis ratio from multiple WSIs. We showed necrosis ratio estimated by our segmentation model highly correlates with necrosis ratio from pathology reports manually assessed by experts where mean absolute differences for Grades IV (100%), III (>=90%), and II (>=50% and <90%) necrosis response are 4.4%, 4.5%, and 17.8%, respectively. We successfully stratified patients to predict overall survival with p=10^-6 and progression-free survival with p=0.012. Our reproducible approach without variability enabled us to tune cutoff thresholds, specifically for our model and our data set, to 80% for OS and 60% for PFS. Our study indicates deep learning can support pathologists as an objective tool to analyze osteosarcoma from histology for assessing treatment response and predicting patient outcome.